Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) and Dyadic International (NASDAQ:DYAI – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.
Profitability
This table compares Kiniksa Pharmaceuticals International and Dyadic International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kiniksa Pharmaceuticals International | 11.58% | 17.27% | 12.64% |
| Dyadic International | -226.85% | -2,920.31% | -93.70% |
Risk and Volatility
Kiniksa Pharmaceuticals International has a beta of 0.07, meaning that its share price is 93% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kiniksa Pharmaceuticals International | 0 | 2 | 8 | 0 | 2.80 |
| Dyadic International | 1 | 0 | 0 | 0 | 1.00 |
Kiniksa Pharmaceuticals International presently has a consensus price target of $102.38, indicating a potential upside of 9.04%. Given Kiniksa Pharmaceuticals International’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Kiniksa Pharmaceuticals International is more favorable than Dyadic International.
Valuation & Earnings
This table compares Kiniksa Pharmaceuticals International and Dyadic International”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kiniksa Pharmaceuticals International | $945.96 million | 7.80 | $59.01 million | $1.30 | 72.22 |
| Dyadic International | $3.09 million | 3.79 | -$7.36 million | ($0.21) | -1.39 |
Kiniksa Pharmaceuticals International has higher revenue and earnings than Dyadic International. Dyadic International is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 27.9% of Dyadic International shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 20.9% of Dyadic International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Kiniksa Pharmaceuticals International beats Dyadic International on 13 of the 14 factors compared between the two stocks.
About Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally. Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.
About Dyadic International
Dyadic International is a biotechnology company developing microbial expression systems to produce proteins for human and animal health applications. Its platforms are designed to help partners develop and manufacture biologics, including vaccines, therapeutics and diagnostic products. The company’s technologies include its C1 fungal expression system, based on a non-pathogenic microorganism, and its Dapibus yeast platform. Dyadic licenses these systems and related expertise to collaborators and also pursues development of selected products for health applications.
Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.
